		-	-				U	7140	_4	J LEM	et lof l		
FORM PTO-14 MODIFIED	49	U.S. LARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DO T NO. 175931 Pec'd PCT/PTO 2.3			SERIAL NO. Unassigned				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							APPLICANT Mitchell et al.						
(Use several sheets if necessary)							DATE ver 23, 199	9	GROUP Unassigned				
			U.S. PAT	ENT DOCUMEN	ΓN	ΓS							
Examiner's Initials		PATENT Number	ISSUE DATE	Name			CLASS	SUBCLASS		FILING DATE IF APPROPRIAT			
	<u> </u>					-							
					_	•							
	<u> </u>			_	_				<u>_</u>				
				-									
							,			<del> , . , . ,</del>			
	. <u> </u>												
	<del> </del>												
,	<del>-1</del>										·-		
	FOREIGN PATENT DOCU  DOCUMENT PUBLICATION					TRANSLATION							
		Number	DATE	Country	Y		CLASS	SUBCLA	ss	YES	No*		
	AA	WO 96/40127	Dec. 19, 1996	WIPO									
	ļ									·			
					_								
				ļ <u>.</u>									
	<u> </u>		<u> </u>	1							<u> </u>		

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
(a)	AB	Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Against Different Neoplastic and						
		Non-Neoplastic Cell Lines," PAACR Annual Meeting, 36, 387 (1995).						
	AC	Monti et al., "DNA Damage and Apoptosis in Human Leukemic Cells Treated with the Piperidine Nitroxyde						
(a)		Tempol," PAACR Annual Meeting, 38, 193 (1997).						
A	AD	Monti et al., "The Piperidine Nitroxyde Tempol Induced Apoptosis and P21-WAF1-CIP1 Expression in P53-						
$(\mathcal{A})$		Deficient Cells," PAACR Annual Meeting, 39, 90 (1998).						
Examiner	Z	DATE CONSIDERED /- 2 } -0 /						
<del></del>								

<sup>\*</sup>A concise statement of relevance is being submitted in lieu of a translation. 37 CFR § 1.98(b). 1449FORM (Rev. 7/15/1999)